Multicenter, open-label, phase 3 (P3) study of Tabelecleucel (Tab-cel) for solid organ (SOT) or allogeneic hematopoietic cell transplant (HCT) recipients with Epstein–Barr virus-driven post transplant lymphoproliferative disease (EBV(+) PTLD) after failure of rituximab (R) or rituximab and chemotherapy (R + C) (ALLELE) Meeting Abstract
| Authors: | Prockop, S. E.; Mahadeo, K. M.; Beitinjaneh, A.; Choquet, S.; Stiff, P.; Reshef, R.; Satyanarayana, G.; Dahiya, S.; Mehta, A.; Dinavahi, R. |
| Abstract Title: | Multicenter, open-label, phase 3 (P3) study of Tabelecleucel (Tab-cel) for solid organ (SOT) or allogeneic hematopoietic cell transplant (HCT) recipients with Epstein–Barr virus-driven post transplant lymphoproliferative disease (EBV(+) PTLD) after failure of rituximab (R) or rituximab and chemotherapy (R + C) (ALLELE) |
| Meeting Title: | 2022 Tandem Meetings of ASTCT and CIBMTR |
| Journal Title: | Transplantation and Cellular Therapy |
| Volume: | 28 |
| Issue: | 3 Suppl. |
| Meeting Dates: | 2022 Apr 23-26 |
| Meeting Location: | Salt Lake City, UT |
| ISSN: | 2666-6375 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2022-03-01 |
| Start Page: | S22 |
| End Page: | S23 |
| DOI: | 10.1016/S2666-6367(22)00184-1 |
| PROVIDER: | manual |
| Notes: | Meeting Abstract: 23 -- Located within the section named "Oral Abstract - Session C - Immune And Gene Therapy" |
